The FDA approved a controlled-release version of Pfizer's Lyrica as a once-daily treatment for diabetic peripheral neuropathy but not for the management of fibromyalgia. The patent on the original formulation expires next December.
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.